Depletion of T Cell Epitopes in Lysostaphin Mitigates Anti-Drug Antibody Response and Enhances Antibacterial Efficacy In Vivo. Issue 5 (21st May 2015)
- Record Type:
- Journal Article
- Title:
- Depletion of T Cell Epitopes in Lysostaphin Mitigates Anti-Drug Antibody Response and Enhances Antibacterial Efficacy In Vivo. Issue 5 (21st May 2015)
- Main Title:
- Depletion of T Cell Epitopes in Lysostaphin Mitigates Anti-Drug Antibody Response and Enhances Antibacterial Efficacy In Vivo
- Authors:
- Zhao, Hongliang
Verma, Deeptak
Li, Wen
Choi, Yoonjoo
Ndong, Christian
Fiering, Steven N.
Bailey-Kellogg, Chris
Griswold, Karl E. - Abstract:
- Summary: The enzyme lysostaphin possesses potent anti-staphylococcal activity and represents a promising antibacterial drug candidate; however, its immunogenicity poses a barrier to clinical translation. Here, structure-based biomolecular design enabled widespread depletion of lysostaphin DRB1 ∗ 0401 restricted T cell epitopes, and resulting deimmunized variants exhibited striking reductions in anti-drug antibody responses upon administration to humanized HLA-transgenic mice. This reduced immunogenicity translated into improved efficacy in the form of protection against repeated challenges with methicillin-resistant Staphylococcus aureus (MRSA). In contrast, while wild-type lysostaphin was efficacious against the initial MRSA infection, it failed to clear subsequent bacterial challenges that were coincident with escalating anti-drug antibody titers. These results extend the existing deimmunization literature, in which reduced immunogenicity and retained efficacy are assessed independently of each other. By correlating in vivo efficacy with longitudinal measures of anti-drug antibody development, we provide the first direct evidence that T cell epitope depletion manifests enhanced biotherapeutic efficacy. Graphical Abstract: Highlights: Lysostaphin is a potent yet immunogenic anti-staphylococcal enzyme Novel algorithms generated highly functional and deimmunized biotherapeutic libraries A T cell epitope-depleted lysostaphin evaded immune recognition in humanized mice T cellSummary: The enzyme lysostaphin possesses potent anti-staphylococcal activity and represents a promising antibacterial drug candidate; however, its immunogenicity poses a barrier to clinical translation. Here, structure-based biomolecular design enabled widespread depletion of lysostaphin DRB1 ∗ 0401 restricted T cell epitopes, and resulting deimmunized variants exhibited striking reductions in anti-drug antibody responses upon administration to humanized HLA-transgenic mice. This reduced immunogenicity translated into improved efficacy in the form of protection against repeated challenges with methicillin-resistant Staphylococcus aureus (MRSA). In contrast, while wild-type lysostaphin was efficacious against the initial MRSA infection, it failed to clear subsequent bacterial challenges that were coincident with escalating anti-drug antibody titers. These results extend the existing deimmunization literature, in which reduced immunogenicity and retained efficacy are assessed independently of each other. By correlating in vivo efficacy with longitudinal measures of anti-drug antibody development, we provide the first direct evidence that T cell epitope depletion manifests enhanced biotherapeutic efficacy. Graphical Abstract: Highlights: Lysostaphin is a potent yet immunogenic anti-staphylococcal enzyme Novel algorithms generated highly functional and deimmunized biotherapeutic libraries A T cell epitope-depleted lysostaphin evaded immune recognition in humanized mice T cell epitope depletion mitigated anti-drug antibodies and improved efficacy in vivo Abstract : Lysostaphin is a potent antibacterial protein that suffers from undesirable immunogenicity in humans. Zhao et al. use innovative computational design algorithms to deplete distributed immunogenic T cell epitopes from lysostaphin, and the deimmunized enzyme proved less immunogenic and more efficacious in treating systemic MRSA infections in humanized mice. … (more)
- Is Part Of:
- Chemistry & biology. Volume 22:Issue 5(2015)
- Journal:
- Chemistry & biology
- Issue:
- Volume 22:Issue 5(2015)
- Issue Display:
- Volume 22, Issue 5 (2015)
- Year:
- 2015
- Volume:
- 22
- Issue:
- 5
- Issue Sort Value:
- 2015-0022-0005-0000
- Page Start:
- 629
- Page End:
- 639
- Publication Date:
- 2015-05-21
- Subjects:
- Biochemistry -- Periodicals
540 - Journal URLs:
- http://www.sciencedirect.com/science/journal/10745521 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.chembiol.2015.04.017 ↗
- Languages:
- English
- ISSNs:
- 1074-5521
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3168.890000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 7367.xml